Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Eli Lilly shareholders can take confidence from the fact that EBIT margins are up from 32% to 39%, and revenue is growing. That's great to see, on both counts. In the chart below, you can see how ...

Eli Lilly (NYSE:LLY) is making a $5.3 billion investment to expand manufacturing for its high-demand anti-obesity drug Zepbound ...

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion recommending approval of its BTK inhibitor ...

A major pharmaceutical company that has invested heavily in North Carolina is planning multiple new factories in the U.S. STORY HIGHLIGHTS Eli Lilly plans $27 billion U.S. expansion, will create ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...